There are currently no disease-modifying medications for the treatment of Huntington’s disease, and current treatment is entirely dependent on symptomatic therapies. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the current treatment landscape of Huntington’s disease and the limitations of current treatment options.
Watch part 2 of this interview, where Prof. Erin Furr-Stimming discusses the use of valbenazine for chorea associated with Huntington disease.
The abstracted entitled: ‘KINECT HD: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine for Chorea Associated with Huntington Disease (HD)‘ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
- Could you give us a brief overview of the current treatment landscape for Huntington disease (HD)? (0:20)
- What are the limitations of current treatment options? (1:10)
Disclosures: Erin Furr-Stimming receives indirect grant/research support from HSG provided by NBI to UTHealth for her role as principal investigator on the Kinect-HD study, and no direct grant/research support remuneration from UniQure, CHDI, HDSA, Cures within Reach, Prilennia, and Roche/Genetech.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Huntington’s Disease
Rajeev Kumar, MDS 2022: ANX005, a humanized monoclonal antibody for Huntington’s disease, the phase 2 study results
The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the key results, their significance and the next steps. The abstract entitled […]
Rajeev Kumar, MDS 2022: The role of complement activation in people living with Huntington’s disease
ANX005, a humanized monoclonal antibody, is designed to inhibit the classical complement pathway which has been associated with Huntington’s disease (HD). In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the role of complement activation in people living with HD and why ANX005 is […]
Esther Cubo, MDS 2022: Insulin-like growth factor-1 and social cognition in Huntington’s disease
This study in patients with Huntington’s disease aimed to assess insulin-like growth factor-1 (IGF-1) levels and hypothalamic function, and the association with non-motor symptoms and brain structure. In this touchNEUROLOGY interview, we speak with Dr Esther Cubo (Hospital Universitario de Burgos, Burgos, Spain) to discuss the study, its findings and future studies that are planned. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!